Overcoming therapy resistance in EGFR-mutant lung cancer.

Abstract

Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR)-activating mutations. Despite prolonged disease control and high tumor response rates, all patients eventually progress on EGFR TKI treatment. Here, we review the mechanisms of acquired EGFR TKI resistance, the methods for monitoring its appearance, as well as current and future efforts to define treatment strategies to overcome resistance.

• Authors: Antonio Passaro, Pasi A Jänne, Tony Mok, Solange Peters
• Journal: Nature cancer (Nat Cancer) Vol. 2 Issue 4 Pg. 377-391 (04 2021) ISSN: 2662-1347 [Electronic] England
• PMID: 35122001 (Publication Type: Journal Article, Review)
• Copyright: © 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.

Chemical References

• Protein Kinase Inhibitors
• EGFR protein, human
• ErbB Receptors

Topics

• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Drug Resistance, Neoplasm (genetics)
• ErbB Receptors (genetics)
• Humans
• Lung Neoplasms (drug therapy)
• Mutation
• Protein Kinase Inhibitors (therapeutic use)